Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low‐dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant‐ineligible patients with newly diagnosed...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Haematol
Prif Awduron: Lu, Jin, Lee, Jae H., Huang, Shang‐Yi, Qiu, Lugui, Lee, Je‐Jung, Liu, Ting, Yoon, Sung‐Soo, Kim, Kihyun, Shen, Zhi X., Eom, Hyeon S., Chen, Wen M., Min, Chang K., Kim, Hyo J., Lee, Jeong O., Kwak, Jae Y., Yiu, Wai, Chen, Guang, Ervin‐Haynes, Annette, Hulin, Cyrille, Facon, Thierry
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2017
Pynciau:
Haematological Malignancy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324608/
https://ncbi.nlm.nih.gov/pubmed/28106903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14465
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg